News

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.
Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...
Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...
Tempus AI, Inc. (NASDAQ:TEM) saw its stock rise 3% on Wednesday following the announcement that the company obtained 510(k) ...
The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.
The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.
An artificial intelligence model developed by Mayo Clinic and Ultromics accurately screens for cardiac amyloidosis using a ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...
Patients with overweight or obesity and heart failure with preserved ejection fraction that have unintentional weight loss have worse outcomes.
The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...
The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure (HF). Now, another drug class has ...
Approval of Kerendia was based on results from the Phase III FINEARTS-HF trial, which demonstrated statistically significant ...